Canfield Gregory S, Chatterjee Anushila, Espinosa Juliel, Mangalea Mihnea R, Sheriff Emma K, Keidan Micah, McBride Sara W, McCollister Bruce D, Hang Howard C, Duerkop Breck A
Division of Infectious Diseases, University of Colorado School of Medicine, Aurora, Colorado, USA.
Department of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, Colorado, USA.
Antimicrob Agents Chemother. 2023 May 1;65(5). doi: 10.1128/AAC.00143-21. Epub 2021 Mar 1.
, a commensal of the human intestine, has emerged as a hospital-adapted, multi-drug resistant (MDR) pathogen. Bacteriophages (phages), natural predators of bacteria, have regained attention as therapeutics to stem the rise of MDR bacteria. Despite their potential to curtail MDR infections, the molecular events governing -phage interactions remain largely unknown. Such interactions are important to delineate because phage selective pressure imposed on will undoubtedly result in phage resistance phenotypes that could threaten the efficacy of phage therapy. In an effort to understand the emergence of phage resistance in , three newly isolated lytic phages were used to demonstrate that phage resistance is conferred through an array of cell wall-associated molecules, including secreted antigen A (SagA), enterococcal polysaccharide antigen (Epa), wall teichoic acids, capsule, and an arginine-aspartate-aspartate (RDD) protein of unknown function. We find that capsule and Epa are important for robust phage adsorption and that phage resistance mutations in , , and enhance susceptibility to ceftriaxone, an antibiotic normally ineffective due to its low affinity for enterococcal penicillin binding proteins. Consistent with these findings, we provide evidence that phages potently synergize with cell wall (ceftriaxone and ampicillin) and membrane-acting (daptomycin) antimicrobials to slow or completely inhibit the growth of Our work demonstrates that the evolution of phage resistance comes with fitness defects resulting in drug sensitization and that lytic phages could serve as effective antimicrobials for the treatment of infections.
作为人类肠道的共生菌,已演变成一种适应医院环境的多重耐药(MDR)病原体。噬菌体作为细菌的天然捕食者,作为遏制MDR细菌兴起的治疗方法重新受到关注。尽管它们有减少MDR感染的潜力,但控制噬菌体与该菌相互作用的分子事件在很大程度上仍不清楚。明确这种相互作用很重要,因为施加在该菌上的噬菌体选择压力无疑会导致噬菌体抗性表型,这可能会威胁噬菌体疗法的疗效。为了了解该菌中噬菌体抗性的出现,使用了三种新分离的裂解性噬菌体来证明该菌的噬菌体抗性是通过一系列与细胞壁相关的分子赋予的,包括分泌抗原A(SagA)、肠球菌多糖抗原(Epa)、壁磷壁酸、荚膜以及一种功能未知的精氨酸-天冬氨酸-天冬氨酸(RDD)蛋白。我们发现荚膜和Epa对于强大的噬菌体吸附很重要,并且该菌中相关基因的噬菌体抗性突变增强了其对头孢曲松的敏感性,头孢曲松是一种由于对肠球菌青霉素结合蛋白亲和力低而通常无效的抗生素。与这些发现一致,我们提供证据表明噬菌体与细胞壁作用(头孢曲松和氨苄西林)和膜作用(达托霉素)抗菌剂有效协同作用,以减缓或完全抑制该菌的生长。我们的工作表明,噬菌体抗性的进化伴随着适应性缺陷导致药物敏感性增加,并且裂解性噬菌体可以作为治疗该菌感染的有效抗菌剂。